New Delhi-based Safex Chemicals has acquired UK-based agrochemical CDMO Briar Chemicals from pan-European alternative investment firm Aurelius in a £73 million deal. Safex is itself backed by a private equity firm, ChrysCapital, and supplies crop protection chemicals. This is its first overseas acquisition.
W. R. Grace & Co. has announced plans to expand its CDMO facility in South Haven, Michigan, by January 2024. It will add an 18 m3 multi-purpose glass-lined and stainless steel reactor train to two existing trains of the same size, as well as a Hastelloy centrifuge to facilitate product isolation.
Hanmi Fine Chemical, an API manufacturing subsidiary of Hanmi Pharmaceutical, has announced plans for a new business offering what it calls ‘high-tech CDMO’ services. It will spend €7.4 million to build facilities for them and expects to form partnerships with more companies in 2H 2022, in addition to the ten it already has.
Japan’s AGC has announced plans for a new, 7,500 m2 building at the site of its AGC Pharma Chemicals Europe CDMO operation in Spain. Costing about $100 million, this is scheduled to begin operation in 1H 2024 and will add 30% to the site’s capacity. This comes on top of a 30% increase in capacity announced in April 2020.
CDMO Flamma has acquired a third API manufacturing facility in Italy from Teva. The Sicor Bulciago site at Lecco has had multiple regulatory inspections. Terms were not disclosed.
“This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites,” said CEO Dr Gianpaolo Negrisoli. “Having the ability to produce more generic APIs in Italy is in line with the European pharmaceutical strategy aiming to reshore.”
India-based CDMO Piramal Pharma has taken a 27.78% equity stake in Yapan Bio of Hyderabad, which provides process development, scale-up and cGMP manufacturing of vaccines and biologics/bio-therapeutics of all kinds, including recombinant and RNA/DNA vaccines, gene therapies and monoclonal antibodies.
As “part of its strategy to meet the evolution of customer needs in fine chemicals and services”, the Minafin Group has reorganised itself into three divisions, each with its own CEO, with effect from 1 October. They are:
* Health Chemistry, comprising the pharmaceutical activities of Minakem CDMO, Minakem Generics and HPAPIs, led by a CEO who is as yet unannounced
* Green Chemistry, comprising the mainly non-pharma activities of Pennakem, Minasolve, Minagro and EcoXtract, under Gust Desmedt